UnitedHealth Rises 4% on Earnings Beat and Raised Full-Year Outlook; Humana Advances 2%

UnitedHealth Group (NYSE:UNH | UNH Price Prediction) shares are up 4% to $395.19 after the health insurer topped Q3 2026 profit estimates and raised its full-year outlook. The beat came on the metric that matters most in managed care, though a reserve release did part of the work.

Meanwhile, Elevance Health (NYSE:ELV) shares are up 2% to $429.47 and Humana (NYSE:HUM) stock is trading 2% higher at $442.01; these gains obviously fall short of the move in UnitedHealth stock. Elevance Health runs a comparable insurance and health services combination at a smaller scale.

The Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is up 0.7% to $173.10, a far smaller advance than the gain in UnitedHealth stock. For a broad-market reading, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is flat at $777.76.

Medical Care Ratio Improvement Powers UnitedHealth’s Beat

UnitedHealth reported third-quarter adjusted earnings per share (EPS) of $4.69 before the opening bell, well ahead of the $4.15 consensus estimate. Management raised its full-year 2026 adjusted EPS outlook again, to at least $20.50, extending a string of upgrades this year. Chief executive Stephen Hemsley weighed in. He stated that the results reflect “the discipline and execution our teams are bringing to every part of our business.”

On the cost side, UnitedHealth’s medical care ratio, the share of premiums paid out on claims, improved to 88.4% from 89.9% a year earlier. This included $610 million of net favorable prior period reserve development. That means money set aside in earlier periods for claims proved larger than needed. A reserve release lifts the quarter and may not repeat, which is what separates a durable result from a flattering one.

Optum Health Rebound Meets Shrinking Membership

UnitedHealth’s Optum Health unit posted operating earnings of $735 million. The unit, part of its Optum health services and pharmacy arm, was up from $41 million a year earlier. The rebound followed UnitedHealth’s exit from value-based care markets where it lacked sufficient scale. That decision also cut Optum Health revenue 10%. Trading revenue for profit in this way gives UnitedHealth a second source of earnings repair beyond insurance pricing.

Elsewhere in Optum, Optum Insight earnings rose to $1.3 billion from $920 million on enhanced product offerings and operational improvements. Optum Rx earnings climbed to $1.7 billion from $1.5 billion, reflecting continued adoption of biosimilars.

UnitedHealthcare, the insurance arm, sees its profitability turn on how much of each premium dollar goes back out in medical costs. Its medical membership slipped to 48.3 million from 50.1 million a year earlier. A decline in its Medicare Advantage and Medicaid enrollment pulled total revenue down 0.4% to $112.69 billion, though the figure still topped estimates.

Humana and Elevance Health, fellow managed care insurers, offer a benchmark for how far UnitedHealth’s report carries among peers. Elevance Health stock’s smaller gain frames the move as company-specific strength with modest impact.

What to Watch Next

What remains unclear is whether the medical care ratio holds its improvement once reserve benefits fade. UnitedHealth’s Medicare Advantage enrollment has also contracted by 935,000 since year-end 2025, which could keep pressure on revenue even as margins recover.

A raised outlook, the Optum Health rebound and $5 billion in share buybacks through September 30 support the bull case. The insurer’s shrinking membership and a quarter helped by reserve releases keep the bear case alive.

Contact [email protected] for any questions or corrections.